Webinar Description:

Complex human diseases are being addressed with increasingly complex biomolecules and technology platforms are integral to the design, development and commercialization of recombinant biotherapeutics. Based on proprietary epigenetic regulatory elements and a proprietary high-performance mammalian cell line (CHO-M), Selexis developed the SUREtechnology Platform, a modular approach that facilitates the effective combination of polypeptides. This approach supports the robust expression of transgenes and enables the combination of metabolism interfering proteins (MiPs) to ease the expression of difficult-to-express scaffolds and streamlines development of CHO research cell banks (RCB) for different molecules. With the production of complex biomolecules such as antibodies, bispecifics, Fc-fusions, cytokines and vaccine antigens, various key challenges are addressed ranging from stable transgene expression, secretory pathways bottlenecks and product quality attributes. Because each drug is unique, we will present three case studies illustrating the benefit of a modular approach to generating high-yield production cell lines.

You will learn:

• An overview of the SUREtechnology Platform™ and Selexis’ modular approach to expressing recombinant proteins
• Diversity of recombinant scaffolds expressed with Selexis’ SUREtechnology Platform™
• Three case studies as examples

Speakers:

Pierre-Alain Girod, PhD
Chief Scientific Officer
Selexis S.A.

Pierre-Alain is a graduate of the University of Lausanne, Department of Plant Biochemistry, in Switzerland, where he also received his PhD. Early in his career, Pierre-Alain completed a postdoctoral fellowship at the University of Wisconsin-Madison in the degradation of proteins by the ubiquitin pathway. He returned to Switzerland in 1993, where he discovered a family of genetic sequences that are involved in the epigenetic regulation of genes. This discovery has subsequently been used to express therapeutic proteins in pharma and biotech. Pierre-Alain has served Selexis as CSO since 2006.

Sonja Delalu, PhD
Director, Business Development and Licensing, Business Development
Selexis S.A.

Sonja is a graduate of the University of Helsinki in Physiology and Neuroscience and later received a PhD in Molecular Neuroimmunology, University of Helsinki, studying protein interactions in the brain, the communication between microglia and neurons, among others.

Cost: No Cost!